313 related articles for article (PubMed ID: 34220825)
1. Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial.
Zhao Y; Li X; Zhou Y; Gao J; Jiao Y; Zhu B; Wu D; Qi X
Front Immunol; 2021; 12():678476. PubMed ID: 34220825
[TBL] [Abstract][Full Text] [Related]
2. Fecal microbiota transfer for refractory intestinal graft-versus-host disease - Experience from two German tertiary centers.
Goeser F; Sifft B; Stein-Thoeringer C; Farowski F; Strassburg CP; Brossart P; Higgins PG; Scheid C; Wolf D; Holderried TAW; Vehreschild MJGT; Cruz Aguilar MR
Eur J Haematol; 2021 Aug; 107(2):229-245. PubMed ID: 33934412
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of 19 cases of steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with fecal microbiota transplantation].
Zheng YY; Yang XT; Lin GQ; Bian MR; Si YJ; Zhang XX; Zhang YM; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):401-407. PubMed ID: 37550190
[No Abstract] [Full Text] [Related]
4. Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study.
Qi X; Li X; Zhao Y; Wu X; Chen F; Ma X; Zhang F; Wu D
Front Immunol; 2018; 9():2195. PubMed ID: 30319644
[TBL] [Abstract][Full Text] [Related]
5. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.
DeFilipp Z; Peled JU; Li S; Mahabamunuge J; Dagher Z; Slingerland AE; Del Rio C; Valles B; Kempner ME; Smith M; Brown J; Dey BR; El-Jawahri A; McAfee SL; Spitzer TR; Ballen KK; Sung AD; Dalton TE; Messina JA; Dettmer K; Liebisch G; Oefner P; Taur Y; Pamer EG; Holler E; Mansour MK; van den Brink MRM; Hohmann E; Jenq RR; Chen YB
Blood Adv; 2018 Apr; 2(7):745-753. PubMed ID: 29592876
[TBL] [Abstract][Full Text] [Related]
6. Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study).
Dougé A; Ravinet A; Corriger A; Cabrespine A; Wasiak M; Pereira B; Sokol H; Nguyen S; Bay JO
BMJ Open; 2023 May; 13(5):e068480. PubMed ID: 37130682
[TBL] [Abstract][Full Text] [Related]
7. Treatment of intestinal graft-versus-host disease with unrelated donor fecal microbiota transplantation capsules: A case report.
Mao D; Jiang Q; Sun Y; Mao Y; Guo L; Zhang Y; Man M; Ouyang G; Sheng L
Medicine (Baltimore); 2020 Sep; 99(38):e22129. PubMed ID: 32957333
[TBL] [Abstract][Full Text] [Related]
8. [Fecal microbiota transplantation for graft-versus-host disease in children and adults: methods, clinical effects, safety].
Goloshchapov OV; Chukhlovin AB; Bakin EA; Stanevich OV; Klementeva RV; Shcherbakov AA; Shvetsov AN; Suvorova MA; Bondarenko SN; Kucher MA; Kulagin AD; Zubarovskaya LS; Moiseev IS
Ter Arkh; 2020 Sep; 92(7):43-54. PubMed ID: 33346444
[TBL] [Abstract][Full Text] [Related]
9. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
10. Outcome of gastrointestinal graft-versus-host disease according to the treatment response.
Tamaki M; Nakasone H; Misaki Y; Yoshimura K; Gomyo A; Hayakawa J; Kusuda M; Akahoshi Y; Ishihara Y; Kawamura K; Tanihara A; Sato M; Terasako-Saito K; Kameda K; Wada H; Kikuchi M; Kimura SI; Kako S; Kanda Y
Ann Hematol; 2018 Oct; 97(10):1951-1960. PubMed ID: 29860563
[TBL] [Abstract][Full Text] [Related]
11. Acute Steroid-Refractory Gastrointestinal Graft-Versus-Host Disease Is Not Associated With Significant Differences in Gut Taxonomic Composition Compared to Steroid-Sensitive Gastrointestinal Graft-Versus-Host Disease Immediately Before Onset of Disease.
Zeng K; Brewster R; Kang JB; Tkachenko E; Brooks E; Bhatt AS; Fodor AA; Andermann TM
Transplant Cell Ther; 2024 Feb; 30(2):237.e1-237.e9. PubMed ID: 37944820
[TBL] [Abstract][Full Text] [Related]
12. Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients.
van Lier YF; Davids M; Haverkate NJE; de Groot PF; Donker ML; Meijer E; Heubel-Moenen FCJI; Nur E; Zeerleder SS; Nieuwdorp M; Blom B; Hazenberg MD
Sci Transl Med; 2020 Aug; 12(556):. PubMed ID: 32801142
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.
Döring M; Cabanillas Stanchi KM; Lenglinger K; Treuner C; Gieseke F; Erbacher A; Mezger M; Vaegler M; Schlegel PG; Greil J; Bettoni da Cunha Riehm C; Faul C; Schumm M; Lang P; Handgretinger R; Müller I
Stem Cells Dev; 2021 Mar; 30(5):234-246. PubMed ID: 33446053
[TBL] [Abstract][Full Text] [Related]
14. Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract.
DeFilipp Z; Damania AV; Kim HT; Chang CC; El-Jawahri A; McAfee SL; Bottoms AS; Toncheva V; Smith MM; Dolaher M; Perry L; White M; Diana B; Connolly S; Dey BR; Frigault MJ; Newcomb RA; O'Donnell PV; Spitzer TR; Mansour MK; Weber D; Ajami NJ; Hohmann E; Jenq RR; Chen YB
Blood Adv; 2024 May; 8(9):2074-2084. PubMed ID: 38471063
[TBL] [Abstract][Full Text] [Related]
15. Fecal microbiota transplantation in the treatment of intestinal steroid-resistant graft-versus-host disease: two case reports and a review of the literature.
Biernat MM; Urbaniak-Kujda D; Dybko J; Kapelko-Słowik K; Prajs I; Wróbel T
J Int Med Res; 2020 Jun; 48(6):300060520925693. PubMed ID: 32527171
[TBL] [Abstract][Full Text] [Related]
16. Endoscopic and Histological Findings Are Predicted by Fecal Calprotectin in Acute Intestinal Graft-Versus-Host-Disease.
Adam B; Koldehoff M; Ditschkowski M; Gromke T; Hlinka M; Trenschel R; Kordeals L; Steckel NK; Beelen DW; Liebregts T
Dig Dis Sci; 2016 Jul; 61(7):2019-26. PubMed ID: 26995779
[TBL] [Abstract][Full Text] [Related]
17. Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD.
Liu Y; Zhao Y; Qi J; Ma X; Qi X; Wu D; Xu Y
Exp Hematol Oncol; 2022 Nov; 11(1):96. PubMed ID: 36352455
[TBL] [Abstract][Full Text] [Related]
18. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
Webb BJ; Brunner A; Ford CD; Gazdik MA; Petersen FB; Hoda D
Transpl Infect Dis; 2016 Aug; 18(4):628-33. PubMed ID: 27214585
[TBL] [Abstract][Full Text] [Related]
19. Effect of GVHD on the gut and intestinal microflora.
Ji H; Feng S; Liu Y; Cao Y; Lou H; Li Z
Transpl Immunol; 2024 Feb; 82():101977. PubMed ID: 38184214
[TBL] [Abstract][Full Text] [Related]
20. Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation.
Modi A; Rybicki L; Majhail NS; Mossad SB
Transpl Infect Dis; 2020 Feb; 22(1):e13217. PubMed ID: 31769584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
